JP MORGAN 2015: Bristol-Myers oncology head boasts PD-1 promise, partners
This article was originally published in Scrip
"The strategy of being able to use immune-oncology to improve outcomes is being realized," Bristol-Myers Squibb head of oncology development Michael Giordano told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco.
You may also be interested in...
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx.